Study endpoints
transaminitis, parasitaemia, Recrudescence, fever
ADVERSE EVENTS, RECURRENCE, PCT
The WHO 2009 treatment outcome criteria were used to assess efficacy [Recrudescence was defined as the recurrence of asexual parasitaemia within 28 days of receiving anti-malarial treatment using the 2021 WHO 2/3 algorithm as stated above for both Day 0 and Day of failure blood spot samples Parasite clearance time (PCT) was defined as the time from the first dose of ACT until the first total and continued disappearance of asexual parasite forms for at least 24 h, whereas fever clearance time (FCT) was defined as the time from the first dose of ACT until the first time the body temperature (for those with a raised temperature at enrolment) drops to below 37.5 °C and stays below 37.5 °C for at least 24 h.During this study, safety was evaluated in terms of adverse events and severe adverse events by examining symptoms, clinical signs, and laboratory parameters. All study participants who took at least one dose of either of the study drugs were evaluated for safety. The evaluation of liver enzymes was a special category that was evaluated due to previous reports of transaminitis [